Opportunities to Enhance Diagnostic Testing and Antimicrobial Stewardship: A Qualitative Multinational Survey of Healthcare Professionals

Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hind...

Full description

Saved in:
Bibliographic Details
Published in:Infectious diseases and therapy Vol. 13; no. 7; pp. 1621 - 1637
Main Authors: Jinks, Timothy, Subramaniam, Sumithra, Bassetti, Matteo, Gales, Ana C., Kullar, Ravina, Metersky, Mark L., Poojary, Aruna, Seifert, Harald, Warrier, Anup, Flayhart, Diane, Kelly, Timothy, Yu, Kalvin, Altevogt, Bruce M., Townsend, Andy, Marsh, Charlotte, Willis, Clare
Format: Journal Article
Language:English
Published: Cheshire Springer Healthcare 01-07-2024
Springer
Springer Nature B.V
Adis, Springer Healthcare
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Methods Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. Results These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). Conclusion AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Plain Language Summary Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance.
AbstractList Abstract Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Methods Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. Results These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). Conclusion AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.
Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful ([greater than or equal to] 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.
Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts.INTRODUCTIONAntimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts.Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses.METHODSThree hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses.These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%).RESULTSThese findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%).AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.CONCLUSIONAMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.
Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Methods Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. Results These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). Conclusion AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Plain Language Summary Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance.
Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.
Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Methods Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. Results These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful ([greater than or equal to] 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). Conclusion AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.
Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance.
IntroductionAntimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts.MethodsThree hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses.ResultsThese findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%).ConclusionAMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.Plain Language SummaryAntimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance.
Audience Academic
Author Warrier, Anup
Flayhart, Diane
Metersky, Mark L.
Townsend, Andy
Subramaniam, Sumithra
Kullar, Ravina
Bassetti, Matteo
Gales, Ana C.
Seifert, Harald
Willis, Clare
Yu, Kalvin
Jinks, Timothy
Poojary, Aruna
Altevogt, Bruce M.
Marsh, Charlotte
Kelly, Timothy
Author_xml – sequence: 1
  givenname: Timothy
  orcidid: 0009-0009-0630-1780
  surname: Jinks
  fullname: Jinks, Timothy
  email: t.jinks@wellcome.org
  organization: Wellcome Trust
– sequence: 2
  givenname: Sumithra
  surname: Subramaniam
  fullname: Subramaniam, Sumithra
  organization: Wellcome Trust
– sequence: 3
  givenname: Matteo
  surname: Bassetti
  fullname: Bassetti, Matteo
  organization: Infectious Diseases Unit, IRCCS San Martino Polyclinic Hospital and Department of Health Sciences (DISSAL), University of Genoa
– sequence: 4
  givenname: Ana C.
  surname: Gales
  fullname: Gales, Ana C.
  organization: Division of Infectious Diseases, Department of Internal Medicine, Universidade Federal de São Paulo - UNIFESP, Escola Paulista de Medicina—EPM
– sequence: 5
  givenname: Ravina
  surname: Kullar
  fullname: Kullar, Ravina
  organization: RM Alden Research Laboratory
– sequence: 6
  givenname: Mark L.
  surname: Metersky
  fullname: Metersky, Mark L.
  organization: Division of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut School of Medicine
– sequence: 7
  givenname: Aruna
  surname: Poojary
  fullname: Poojary, Aruna
  organization: Department of Pathology & Microbiology, Breach Candy Hospital Trust
– sequence: 8
  givenname: Harald
  surname: Seifert
  fullname: Seifert, Harald
  organization: Institute for Medical Microbiology, Immunology, and Hygiene, Medical Faculty and University Hospital Cologne University of Cologne, German Center for Infection Research (DZIF), Institute of Translational Research, CECAD Cluster of Excellence, University of Cologne
– sequence: 9
  givenname: Anup
  surname: Warrier
  fullname: Warrier, Anup
  organization: Aster Medcity
– sequence: 10
  givenname: Diane
  surname: Flayhart
  fullname: Flayhart, Diane
  organization: Beckton, Dickinson and Company
– sequence: 11
  givenname: Timothy
  surname: Kelly
  fullname: Kelly, Timothy
  organization: Beckton, Dickinson and Company
– sequence: 12
  givenname: Kalvin
  surname: Yu
  fullname: Yu, Kalvin
  organization: Beckton, Dickinson and Company
– sequence: 13
  givenname: Bruce M.
  surname: Altevogt
  fullname: Altevogt, Bruce M.
  organization: bioMérieux
– sequence: 14
  givenname: Andy
  surname: Townsend
  fullname: Townsend, Andy
  organization: Pfizer Inc
– sequence: 15
  givenname: Charlotte
  surname: Marsh
  fullname: Marsh, Charlotte
  organization: Genesis Research
– sequence: 16
  givenname: Clare
  surname: Willis
  fullname: Willis, Clare
  organization: Genesis Research
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38829440$$D View this record in MEDLINE/PubMed
BookMark eNp9UstuFDEQHKEgAkt-gAOyxIXLBL_mYS5oFQKJFBQQ4Wz1zrR3Hc3aiz0TlE_gr-nNhoQghHxoy11VVnXXs2IvxIBF8ULwQ8F58yZrLqQoudQl58bUpXhUPJXCqLJWrdy7vbdSmv3iIOdLzgnfamGaJ8W-altptOZPi5_nm01M4xT86DGzMbLjsILQIXvvYRliHn3HLpBKWDIIPZuH0a99l-LCw8C-jvgDUp9XfvOWzdmXCQY_wuivkH2aBiLRPYYtcEpXeM2iYycIw7jqICH7nKLDnG8Q-Xnx2FHBg9s6K759OL44OinPzj-eHs3Pyk63ZiwNaNPzWjeu6kAir6BVte67uml6WVduAaqquFwgYIP9wikBPTjgwOuq6pxRs-J0p9tHuLSb5NeQrm0Eb28eYlpaSOR6QCtaDaJV0DuhNLaLViilAMG5vm466syKdzutzbRYY99hGBMMD0QfdoJf2WW8soJ2ZxquSeH1rUKK3yeas1373OEwQMA4ZavIqtBSyJqgr_6CXsYpbUdHqIaGU1WNvEctgRz44CJ93G1F7bwxxghdkYtZcfgPFJ0eabmUNOfp_QFB7gi0-ZwTujuTgtttIO0ukJYCaW8CaQWRXv45njvK7_gRQO0AmVphiene0n9kfwH7a-87
Cites_doi 10.1093/jacamr/dlz072
10.1007/s40121-023-00815-z
10.2146/ajhp170604
10.1017/ice.2021.149
10.1016/j.diagmicrobio.2020.115219
10.1373/jalm.2018.026450
10.1016/s1473-3099(13)70250-0
10.1007/s10096-020-04031-2
10.1093/jac/dku497
10.3109/10408363.2015.1054984
10.3310/hta19960
10.1016/j.jval.2020.11.008
10.1016/s0140-6736(21)02724-0
10.1007/s00134-017-4683-6
10.1093/cid/ciw649
10.1093/cid/ciz406
10.3390/antibiotics11030308
10.1039/c7md00528h
10.1093/cid/ciaa1527
10.1016/j.ajic.2018.02.022
10.1093/cid/ciab910
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
COPYRIGHT 2024 Springer
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 Springer
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
NPM
AAYXX
CITATION
3V.
7RV
7X7
7XB
8AO
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1007/s40121-024-00996-1
DatabaseName Springer Nature OA Free Journals
PubMed
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database (ProQuest)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Public Health Database (ProQuest)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Nursing & Allied Health Premium
Publicly Available Content Database (Proquest) (PQ_SDU_P3)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Public Health
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic

PubMed


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
Education
EISSN 2193-6382
EndPage 1637
ExternalDocumentID oai_doaj_org_article_184a183adf134e8b81333aeaffd67c18
A799914513
10_1007_s40121_024_00996_1
38829440
Genre Journal Article
GeographicLocations Brazil
United States
China
Germany
India
GeographicLocations_xml – name: China
– name: Germany
– name: United States
– name: India
– name: Brazil
GroupedDBID -A0
0R~
2VQ
3V.
4.4
53G
5VS
7RV
7X7
8AO
8C1
8FI
8FJ
AAKKN
AAYZJ
ABDBF
ABEEZ
ABUWG
ACACY
ACGFS
ACULB
ADBBV
ADINQ
ADRAZ
AFGXO
AFKRA
AHBXF
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BKEYQ
BPHCQ
BVXVI
C24
C6C
CCPQU
DIK
EBS
EJD
ESX
FYUFA
GROUPED_DOAJ
HMCUK
HYE
HZ~
IAO
KQ8
M48
M~E
NAPCQ
O9-
OK1
PIMPY
PQQKQ
PROAC
RPM
RSV
SISQX
SMD
SOJ
UKHRP
~JE
ITC
NPM
AAYXX
CITATION
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c489t-9a49d0647f5ca2e05a8364dc677d265fba35502beae7edbf31adafa0a0655cf93
IEDL.DBID RPM
ISSN 2193-8229
IngestDate Tue Oct 22 15:17:13 EDT 2024
Tue Sep 17 21:28:42 EDT 2024
Sat Oct 26 04:24:04 EDT 2024
Thu Oct 10 23:01:03 EDT 2024
Tue Nov 19 21:33:25 EST 2024
Tue Nov 12 23:38:46 EST 2024
Thu Sep 26 21:37:21 EDT 2024
Sat Nov 02 12:24:50 EDT 2024
Thu Jul 04 05:09:18 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Antimicrobial stewardship
Bacteria and bacterial infections
Antimicrobial resistance
Healthcare professional survey
Diagnostic technologies
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c489t-9a49d0647f5ca2e05a8364dc677d265fba35502beae7edbf31adafa0a0655cf93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0009-0009-0630-1780
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219704/
PMID 38829440
PQID 3074895572
PQPubID 2034749
PageCount 17
ParticipantIDs doaj_primary_oai_doaj_org_article_184a183adf134e8b81333aeaffd67c18
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11219704
proquest_miscellaneous_3064142126
proquest_journals_3074895572
gale_infotracmisc_A799914513
gale_infotracacademiconefile_A799914513
crossref_primary_10_1007_s40121_024_00996_1
pubmed_primary_38829440
springer_journals_10_1007_s40121_024_00996_1
PublicationCentury 2000
PublicationDate 2024-07-01
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Cheshire
PublicationPlace_xml – name: Cheshire
– name: New Zealand
– name: Philadelphia
PublicationTitle Infectious diseases and therapy
PublicationTitleAbbrev Infect Dis Ther
PublicationTitleAlternate Infect Dis Ther
PublicationYear 2024
Publisher Springer Healthcare
Springer
Springer Nature B.V
Adis, Springer Healthcare
Publisher_xml – name: Springer Healthcare
– name: Springer
– name: Springer Nature B.V
– name: Adis, Springer Healthcare
References O'Neill J. Rapid diagnostics: stopping unnecessary use of antibiotics. 2015. https://amr-review.org/sites/default/files/Paper-Rapid-Diagnostics-Stopping-Unnecessary-Prescription-Low-Res.pdf. Accessed 28 May 2024.
RhodesAEvansLEAlhazzaniWSurviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016Intensive Care Med201743330437710.1007/s00134-017-4683-628101605
National Centre for Disease Control India. National Treatment Guidelines for Antimicrobial Use in Infectious Diseases. 2016. https://health.punjab.gov.in/sites/default/files/AMR_guideline7001495889.pdf. Accessed 28 May 2024.
ApisarnthanarakABin KimHMooreLSPUtility and applicability of rapid diagnostic testing in antimicrobial stewardship in the Asia-Pacific region: a Delphi consensusClin Infect Dis20227411206720761:CAS:528:DC%2BB38Xhs1ehsLnE10.1093/cid/ciab91034665855
HowardPPulciniCLevy HaraGAn international cross-sectional survey of antimicrobial stewardship programmes in hospitalsJ Antimicrob Chemother2015704124512551:CAS:528:DC%2BC2MXhsFahtL3J10.1093/jac/dku49725527272
European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-NET) Annual Epidemiological Report 2021. Stockholm: ECDC; 2022.
The World Bank. GNI per capita, Atlas method (current US$). https://data.worldbank.org/indicator/NY.GNP.PCAP.CD. Accessed 18 Apr 2023.
BriggsNCampbellSGuptaSAdvances in rapid diagnostics for bloodstream infectionsDiagn Microbiol Infect Dis20219911:CAS:528:DC%2BB3cXitVSrt7nP10.1016/j.diagmicrobio.2020.11521933059201
World Health Organization. Global antimicrobial resistance and use surviellance system (GLASS) report. 2022. https://iris.who.int/bitstream/handle/10665/364996/9789240062702-eng.pdf?sequence=1. Accessed 28 May 2024.
Sriram A, Kalanxhi E, Kapoor G, et al. In: Atwater S, editor. The state of the world's antibiotics 2021: a global analysis of antimicrobial resistance and its drivers. Washington, DC: Center for Disease Dynamics, Economics & Policy; 2021.
European Committee on Antimicrobal Suceptibility Testing (EUCAST). Rapid AST directly from blood culture bottles. https://www.eucast.org/rapid_ast_in_bloodcultures. Accessed 16 May 2023.
EhrenKMeißnerAJazmatiNClinical impact of rapid species identification from positive blood cultures with same-day phenotypic antimicrobial susceptibility testing on the management and outcome of bloodstream infectionsClin Infect Dis20207071285129310.1093/cid/ciz40631094414
ApisarnthanarakAKimHBMooreLRapid diagnostic testing for antimicrobial stewardship: utility in Asia PacificInfect Control Hosp Epidemiol202142786486810.1017/ice.2021.14934128462
BeganovicMMcCrearyEKMahoneyMVDionneBGreenDATimbrookTTInterplay between rapid diagnostic tests and antimicrobial stewardship programs among patients with bloodstream and other severe infectionsJ Appl Lab Med2019346016161:CAS:528:DC%2BC1MXhtFSrs77I10.1373/jalm.2018.02645031639729
MelanderRJZurawskiDVMelanderCNarrow-spectrum antibacterial agentsMedchemcomm20189112211:CAS:528:DC%2BC2sXhslKqsr3J10.1039/c7md00528h29527285
Westwood M, Ramaekers B, Whiting P, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health technology assessment. 2015;19(96):v-xxv, 1–236. https://www.ncbi.nlm.nih.gov/books/NBK327098/.
ErasmusRSahniSEl-SharkawyRConnectivity strategies in managing a POCT serviceEJIFCC2021322190194344214878343042
AugustovskiFAlfieVAlcarazAGarcía MartíSDrummondMFPichon-RiviereAA value framework for the assessment of diagnostic technologies: a proposal based on a targeted systematic review and a multistakeholder deliberative process in Latin AmericaValue Health202124448649610.1016/j.jval.2020.11.00833840426
PooleSTownsendJWertheimHHow are rapid diagnostic tests for infectious diseases used in clinical practice: a global survey by the International Society of Antimicrobial Chemotherapy (ISAC)Eur J Clin Microbiol Infect Dis202140242943410.1007/s10096-020-04031-232902760
QuinnADDixonDMeenanBJBarriers to hospital-based clinical adoption of point-of-care testing (POCT): a systematic narrative reviewCrit Rev Clin Lab Sci201653111210.3109/10408363.2015.105498426292075
DrainPKHyleEPNoubaryFDiagnostic point-of-care tests in resource-limited settingsLancet Infect Dis201414323924910.1016/s1473-3099(13)70250-024332389
O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Government of the United Kingdom; 2016. https://apo.org.au/node/63983. Accessed 28 May 2024.
Infectious Diseases Society of America (IDSA). Better tests, better care: the promise of next generation diagnostics. 2015. https://www.idsociety.org/globalassets/idsa/policy--advocacy/current_topics_and_issues/diagnostics/statements/better-tests-better-care-for-policymakers.pdf. Accessed 28 May 2024.
EdmistonCEGarciaRBarndenMDeBaunBJohnsonHBRapid diagnostics for bloodstream infections: a primer for infection preventionistsAm J Infect Control20184691060106810.1016/j.ajic.2018.02.02229661630
MooreLSPVillegasMVWenzlerERapid diagnostic test value and implementation in antimicrobial stewardship across low-to-middle and high-income countries: a mixed-methods reviewInfect Dis Ther20231261445146310.1007/s40121-023-00815-z3726161210233178
World Health Organization. Global action plan on antimicrobial resistance. 2015. https://iris.who.int/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1. Accessed 28 May 2024.
Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit. JAC Antimicrob Resist. 2019;1(3):dlz072. https://doi.org/10.1093/jacamr/dlz072.
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. https://doi.org/10.1016/s0140-6736(21)02724-0.
Trevas D, Caliendo AM, Hanson K, Levy J, Ginocchio CC, for the Infectious Diseases Society of America. Diagnostic tests can stem the threat of antimicrobial resistance: infectious disease professionals can help. Clin Infect Dis 2020;72(11):893-900. https://doi.org/10.1093/cid/ciaa1527.
MoradoFWongDWApplying diagnostic stewardship to proactively optimize the management of urinary tract infectionsAntibiotics202211310.3390/antibiotics11030308
WenzlerETimbrookTTWongJRHurstJMMacVaneSHImplementation and optimization of molecular rapid diagnostic tests for bloodstream infectionsAm J Health Syst Pharm20187516119112021:CAS:528:DC%2BC1MXivV2mur8%3D10.2146/ajhp17060429970407
TimbrookTTMortonJBMcConeghyKWCaffreyARMylonakisELaPlanteKLThe effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysisClin Infect Dis2016641152310.1093/cid/ciw64927678085
A Apisarnthanarak (996_CR7) 2022; 74
S Poole (996_CR19) 2021; 40
R Erasmus (996_CR20) 2021; 32
AD Quinn (996_CR21) 2016; 53
996_CR4
996_CR5
996_CR6
996_CR1
996_CR2
996_CR3
F Morado (996_CR32) 2022; 11
996_CR27
M Beganovic (996_CR14) 2019; 3
996_CR24
RJ Melander (996_CR28) 2018; 9
996_CR25
996_CR23
A Apisarnthanarak (996_CR29) 2021; 42
P Howard (996_CR22) 2015; 70
A Rhodes (996_CR26) 2017; 43
N Briggs (996_CR10) 2021; 99
CE Edmiston (996_CR11) 2018; 46
F Augustovski (996_CR31) 2021; 24
996_CR8
996_CR9
K Ehren (996_CR13) 2020; 70
TT Timbrook (996_CR12) 2016; 64
996_CR17
996_CR16
E Wenzler (996_CR15) 2018; 75
LSP Moore (996_CR18) 2023; 12
PK Drain (996_CR30) 2014; 14
References_xml – ident: 996_CR17
  doi: 10.1093/jacamr/dlz072
– ident: 996_CR3
– volume: 12
  start-page: 1445
  issue: 6
  year: 2023
  ident: 996_CR18
  publication-title: Infect Dis Ther
  doi: 10.1007/s40121-023-00815-z
  contributor:
    fullname: LSP Moore
– ident: 996_CR23
– volume: 75
  start-page: 1191
  issue: 16
  year: 2018
  ident: 996_CR15
  publication-title: Am J Health Syst Pharm
  doi: 10.2146/ajhp170604
  contributor:
    fullname: E Wenzler
– ident: 996_CR5
– ident: 996_CR25
– volume: 42
  start-page: 864
  issue: 7
  year: 2021
  ident: 996_CR29
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1017/ice.2021.149
  contributor:
    fullname: A Apisarnthanarak
– ident: 996_CR27
– volume: 99
  issue: 1
  year: 2021
  ident: 996_CR10
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2020.115219
  contributor:
    fullname: N Briggs
– volume: 32
  start-page: 190
  issue: 2
  year: 2021
  ident: 996_CR20
  publication-title: EJIFCC
  contributor:
    fullname: R Erasmus
– volume: 3
  start-page: 601
  issue: 4
  year: 2019
  ident: 996_CR14
  publication-title: J Appl Lab Med
  doi: 10.1373/jalm.2018.026450
  contributor:
    fullname: M Beganovic
– volume: 14
  start-page: 239
  issue: 3
  year: 2014
  ident: 996_CR30
  publication-title: Lancet Infect Dis
  doi: 10.1016/s1473-3099(13)70250-0
  contributor:
    fullname: PK Drain
– volume: 40
  start-page: 429
  issue: 2
  year: 2021
  ident: 996_CR19
  publication-title: Eur J Clin Microbiol Infect Dis
  doi: 10.1007/s10096-020-04031-2
  contributor:
    fullname: S Poole
– volume: 70
  start-page: 1245
  issue: 4
  year: 2015
  ident: 996_CR22
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dku497
  contributor:
    fullname: P Howard
– volume: 53
  start-page: 1
  issue: 1
  year: 2016
  ident: 996_CR21
  publication-title: Crit Rev Clin Lab Sci
  doi: 10.3109/10408363.2015.1054984
  contributor:
    fullname: AD Quinn
– ident: 996_CR16
  doi: 10.3310/hta19960
– volume: 24
  start-page: 486
  issue: 4
  year: 2021
  ident: 996_CR31
  publication-title: Value Health
  doi: 10.1016/j.jval.2020.11.008
  contributor:
    fullname: F Augustovski
– ident: 996_CR2
– ident: 996_CR1
  doi: 10.1016/s0140-6736(21)02724-0
– volume: 43
  start-page: 304
  issue: 3
  year: 2017
  ident: 996_CR26
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-017-4683-6
  contributor:
    fullname: A Rhodes
– ident: 996_CR24
– ident: 996_CR4
– volume: 64
  start-page: 15
  issue: 1
  year: 2016
  ident: 996_CR12
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciw649
  contributor:
    fullname: TT Timbrook
– ident: 996_CR6
– volume: 70
  start-page: 1285
  issue: 7
  year: 2020
  ident: 996_CR13
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz406
  contributor:
    fullname: K Ehren
– ident: 996_CR8
– volume: 11
  start-page: 3
  year: 2022
  ident: 996_CR32
  publication-title: Antibiotics
  doi: 10.3390/antibiotics11030308
  contributor:
    fullname: F Morado
– volume: 9
  start-page: 12
  issue: 1
  year: 2018
  ident: 996_CR28
  publication-title: Medchemcomm
  doi: 10.1039/c7md00528h
  contributor:
    fullname: RJ Melander
– ident: 996_CR9
  doi: 10.1093/cid/ciaa1527
– volume: 46
  start-page: 1060
  issue: 9
  year: 2018
  ident: 996_CR11
  publication-title: Am J Infect Control
  doi: 10.1016/j.ajic.2018.02.022
  contributor:
    fullname: CE Edmiston
– volume: 74
  start-page: 2067
  issue: 11
  year: 2022
  ident: 996_CR7
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciab910
  contributor:
    fullname: A Apisarnthanarak
SSID ssj0001284197
Score 2.3280582
Snippet Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS)...
Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include...
Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS)...
IntroductionAntimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS)...
Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may...
Abstract Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1621
SubjectTerms Antibiotics
Antimicrobial agents
Antimicrobial resistance
Antimicrobial stewardship
Bacteria and bacterial infections
Clinical outcomes
Diagnostic technologies
Diagnostic tests
Drug resistance
Education
Health care
Healthcare professional survey
Hospital costs
Infectious Diseases
Internal Medicine
Literature reviews
Medical colleges
Medical diagnosis
Medical equipment and supplies industry
Medical personnel
Medical test kit industry
Medical tests
Medicine
Medicine & Public Health
Original Research
Parasites
Pharmaceutical industry
Polls & surveys
Public health
Surveys
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgD4gL4k1gQUZC4gAWcfxIwq2wXfXCQ-oicbOc2GZ7WHfVNkj8BP41M04amkWIC9fYjux5eGbsmc-EvFCFLMGQlazhTjHJc8fAbxasVtJb0TZ1SGj7i2X58Wt1MkeYnPGpL8wJ6-GBe8K9gQjEgthZF7iQvmoqCKqE9TYEp8uW92W-uT4IpvrTlUry9LIKaKRgiGo-VMykujmJSGYMzBNDD0kzPrFKCbz_zy36wEZdzZ-8comabNPpbXJrcCrprF_MHXLNx7vkxofh2vwe-fnpEt3sLib4VLpb03k8R3bTkz7TDsbRM8TbiN-ojY7O4m51sUoYTfDfJR6wbRzmdb2lM9rDbiTAcJrqd_cHinTZbb77H3Qd6GJMK6OfD8A_tvfJl9P52fsFG95gYK2s6h2rrawdFqQG1drC58pWQkvX6rJ0hVahseCw5EXjrS-9a4Lg1tlgcwuujWpDLR6Qo7iO_hGh4DwG3ACk0K2sK9U4UUMHjTe7GqK2jLza88Bc9lAbZgRVThwzwDGTOGZ4Rt4hm8aeCJOdPoDwmEF4zL-EJyMvkckGlRk42dqhJgEmjLBYZlai_ywVFxk5nvQEJWynzXsxMcMmsDWwfQINlSqLjDwfm3EkJrZFv-6wj5Ycb-V1Rh72UjUuSUD0U0uZZ6SayNtkzdOWuDpPEOHgRYP450DT13vR_D2vvxP18f8g6hNys0iqhTnNx-Rot-n8U3J967pnSUl_AbMMPVA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: SpringerOpen
  dbid: C24
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSIgLb0qgICMhcQCjJH4k4ba0W-2Fh7RF4mY5sd2uEE61u0HiJ_CvmXGyoSlwgGs8ieLxvOyZ-UzIc5mLAhxZwerMSiay1DKImzmrpHCGN3XlI9r-Ylm8_1wezREmh49HF-HL611GMhrqsddNIPoYA5fCMKpRDLY81yB4EHhtweHQ4tAfrJQii5eqgDJyhoDmQ7PMnz8zcUgRt_9363zBPV0unbyUP41u6fjWf03oNrk5RKF01ovNHXLFhbvk-rshz36P_PhwjnF5FyLeKt22dB7OUD7oUV-aB-_REwToCKfUBEtnYbv6uoqgTvDdJZ7IrS0Wgr2hM9rjdESEcRobfncnkHTZrb-577T1dDHWodGPF9BCNvfJp-P5yeGCDZc2sEaU1ZZVRlQWO1i9bEzuUmlKroRtVFHYXElfG4hw0rx2xhXO1p5nxhpvUgOxkGx8xR-QvdAG95BQiDY9WgzBVSOqUtaWV0CgMBWsYJuXkJe7ldPnPTaHHlGYI3c1cFdH7uosIW9xcUdKxNWOD9r1qR7UVMN-14CRM9ZnXLiyLmELz40z3ltVNFmZkBcoGhq1H9a_MUMTA_ww4mjpWYEBt5AZT8jBhBK0tpkO74RLD1Zjo8HeAg-lLPKEPBuH8U2shAuu7ZBGiQzT-Coh-70sjlPisF2qhEgTUk6kdDLn6UhYnUVMcQi7QWlS4OmrnbT--q-_M_XRv5E_JjfyKPBY7nxA9rbrzj0hVze2exqV-Cen_T9S
  priority: 102
  providerName: Springer Nature
Title Opportunities to Enhance Diagnostic Testing and Antimicrobial Stewardship: A Qualitative Multinational Survey of Healthcare Professionals
URI https://link.springer.com/article/10.1007/s40121-024-00996-1
https://www.ncbi.nlm.nih.gov/pubmed/38829440
https://www.proquest.com/docview/3074895572
https://www.proquest.com/docview/3064142126
https://pubmed.ncbi.nlm.nih.gov/PMC11219704
https://doaj.org/article/184a183adf134e8b81333aeaffd67c18
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELboHhAXxJvAUhkJiQN4t4kfSbiVble9LKzUReJmObG9W2nrVn0g8RP418w4SWkXceEaOw9nHv48nvlMyDuZiRwmspxVqZVMpAPLADdzVkrhDK-r0ke2_ck0__K9OBsjTY7qamFi0n5dzU7C7fwkzG5ibuVyXp92eWKnlxcjwAhpmQ_EaY_0ABzurdGbyEoh0niqCvTiDBnN22qZWDMnkMWMwdTEEB0phmfFcMCZpcAAyN7kFDn8__bUe1PV3TTKO3upcYo6f0QettiSDpsxPCb3XHhC7l-0u-dPya-vS0Tb2xBZVOlmQcfhBqVOz5qEO7iPXiHtRrimJlg6DJvZfBapmuC5U4yzrSymd32iQ9qwb0TecBrLeLu4Ip1uVz_cT7rwdLLLLqOXexwg62fk2_n4ajRh7VEMrBZFuWGlEaXFulQva5O5gTQFV8LWKs9tpqSvDOCWQVY543JnK89TY403AwMIR9a-5M_JUVgE95JQwJAe_YDgqhZlISvLS-igcINXweItIR86Gehlw7ihd9zKUXgahKej8HSakM8opl1PZMuOFxara93qjIZVrAHXZaxPuXBFVcDCnBtnvLcqr9MiIe9RyBptGiRZm7Y0AT4Y2bH0MEcYLWTKE3J80BNssT5s7tREt75grcGLwj-UMs8S8nbXjHdifltwiy32USLFzXmVkBeNVu2G1ClnQooDfTsY82ELGE5kCu8MJSEfO9X8813__qmv_v9Nr8mDLNoWJjQfk6PNauvekN7abvukN8pEPwY9-tFifwPb3D91
link.rule.ids 230,315,729,782,786,866,887,2106,27933,27934,41128,42197,52242,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSMCFdyFQwEhIHMBSEtt5cFvarRbRFqRdJG6WE9vtHvBWuxskfgL_mhnnQVPgANd4EsWTeXpmvhDyUqYiB0eWsyoxkokkNgziZs5KKazmdVW6gLY_m-cnX4qDKcLkiH4WJnS79yXJYKmHYTeB8GMMfArDsCZjkPNcE6BwmHLtdzMO7clKIZLwVxVY5AwRzbtpmT8_ZuSRAnD_7-b5gn-63Dt5qYAa_NLh7f_b0R1yq4tD6aQVnLvkivX3yPXjrtJ-n_z4eI6ReeMD4irdrujUn6GE0IO2OQ_uowuE6PCnVHtDJ367_LoMsE7w3Dmeya0NtoK9pRPaInUEjHEaRn77M0g6b9bf7He6cnQ2dKLRTxfwQjYPyOfD6WJ_xrrfNrBaFOWWlVqUBmdYnax1amOpC54JU2d5btJMukpDjBOnldU2t6ZyPNFGOx1riIZk7Uq-S3b8yttHhEK86dBmCJ7VoixkZXgJBBkWgzNI9CLyuv906rxF51ADDnPgrgLuqsBdlUTkHX7dgRKRtcOF1fpUdYqqIOPVYOa0cQkXtqgKSOK5tto5k-V1UkTkFcqGQv0HAah1N8YAL4xIWmqSY8gtZMIjsjeiBL2tx8u9dKnObmwUWFzgoZR5GpEXwzLeib1w3q4apMlEgoX8LCIPW2EctsQhYSqFiCNSjMR0tOfxil-eBVRxCLxBa2Lg6ZteWn-919-Z-vjfyJ-TG7PF8ZE6en_y4Qm5mQbhx-bnPbKzXTf2Kbm6Mc2zoNE_AX6YQyw
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSBUX3o9AASMhcQCrSWznwW3p7moRUCptkbhZTmy3e8BZ7QOJn8C_ZsbJhqbAAXGNJ1E8madn5gshL2QqcnBkOasSI5lIYsMgbuaslMJqXlelC2j7s3l-_KUYTxAmp5_iD93uu5JkO9OAKE1-c7g07rAffBMIRcbAvzAMcTIG-c81AaEDNnUddfMO7SlLIZLwhxXQTM4Q3bybnPnzYwbeKYD4_26qL_iqy32Ul4qpwUdNb_7_7m6RG118SketQN0mV6y_Q_Y_dhX4u-THpyVG7FsfkFjppqETf46SQ8dt0x7cR08RusOfUe0NHfnN4usiwD3Bc-d4Vrcy2CL2ho5oi-ARsMdpGAXenU3S-Xb1zX6njaOzvkONnlzAEVnfI5-nk9OjGet-58BqUZQbVmpRGpxtdbLWqY2lLngmTJ3luUkz6SoNsU-cVlbb3JrK8UQb7XSsIUqStSv5fbLnG28fEgpxqENbInhWi7KQleElEGRYJM4gAYzIq91nVMsWtUP1-MyBuwq4qwJ3VRKRt_ile0pE3A4XmtWZ6hRYQSaswfxp4xIubFEVkNxzbbVzJsvrpIjIS5QThXYBhKHW3XgDvDAibKlRjqG4kAmPyMGAEvS5Hi7vJE119mStwBIDD6XM04g875fxTuyR87bZIk0mEizwZxF50ApmvyUOiVQpRByRYiCygz0PV_ziPKCNg1aBBsXA09c7yf31Xn9n6qN_I39G9k_GU_Xh3fH7x-R6GmQfe6IPyN5mtbVPyNW12T4Nyv0T5A5MBw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Opportunities+to+Enhance+Diagnostic+Testing+and+Antimicrobial+Stewardship%3A+A+Qualitative+Multinational+Survey+of+Healthcare+Professionals&rft.jtitle=Infectious+diseases+and+therapy&rft.au=Jinks%2C+Timothy&rft.au=Subramaniam%2C+Sumithra&rft.au=Bassetti%2C+Matteo&rft.au=Gales%2C+Ana+C.&rft.date=2024-07-01&rft.pub=Springer+Healthcare&rft.issn=2193-8229&rft.eissn=2193-6382&rft.volume=13&rft.issue=7&rft.spage=1621&rft.epage=1637&rft_id=info:doi/10.1007%2Fs40121-024-00996-1&rft.externalDocID=10_1007_s40121_024_00996_1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2193-8229&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2193-8229&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2193-8229&client=summon